ClinicalTrials.gg
CompletedNCT06140433VSCUpdated Jul 5, 2024

Vital Signs Camera Study

An interventional study of VSC-MEDlib in Respiration Rate and Heart Rate, sponsored by Philips Clinical & Medical Affairs Global. Completed at 1 site in Netherlands. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-05.

Sponsored by Philips Clinical & Medical Affairs Global (part of Philips) · Not applicable, Interventional, and Screening

Phase
Not applicable
Study type
Interventional
Enrollment
94
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study is a single center, prospective clinical investigation which is balanced for gender, age, Body Mass Index (BMI) and skin color. Simultaneous measurements of PR and RR on study participants will be collected in conditions described in IFU and various suboptimal conditions. The study participants will be recorded with the VSC demo app (together with a compatible camera and computing hardware) and reference devices. PR and RR data to be collected by the VSC demo app, will be post-processed after the clinical investigation and compared with the reference devices. Persons who are willing to participate will be asked to provide their consent.

Primary objective:

  • To assess the clinical safety and effectiveness of Pulse Rate (PR) and Respiration Rate (RR) measured with the VSC-MEDlib within the intended use compared to the gold-standard reference devices.

Exploratory objective:

  • To assess the clinical safety and effectiveness of Pulse Rate and Respiration Rate measured with the VSC-MEDlib during suboptimal circumstances (outside the scope of the intended use), compared to the gold-standard reference devices.
02

Conditions studied

  • Respiration Rate
  • Heart Rate
03

In context

Lead sponsor

Philips Clinical & Medical Affairs Global is the lead sponsor of 84 studies on the registry; 24 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 11 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Persons with ASA I or II classification
  • Adult population (age >18 years old)
  • BMI ≥ 18 - ≤ 40 kg/m2
  • Able to intensively exercise for 10 minutes
  • Persons willing to give informed consent
  • Willingness to have vital signs measured by a medical mobile application
  • Willingness to follow study protocol (e.g., put on sunglasses, facial make-up, medical face-mask and sitting still up to 2 minutes)

Exclusion criteria

Exclusion Criteria:

  • Vulnerable populations (e.g., age \<18 years old, not able to consent by themselves, or immunecompromised or pregnant women)
  • Cardiac arrhythmias (e.g., Atrial Fibrillation, Supraventricular Tachycardia, Ventricular arrhythmia, regular ectopic beats)
  • Persons present signs of infection
  • Participant has known allergic reactions to make-up and/or make-up remover
  • Persons with positive COVID 19 test in last 14 days
  • Participant who exhibit irregular or excessive movement such as tremors, tics, shaking and/or shivering
  • Participant is Philips employee or their family members residing with this Philips employee.
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
94 participants (actual)

Study arms

  • Other
    VSC-MEDlib

    SaMD: Data collection study. Software to be applied after data collection.

    Device: VSC-MEDlib

Interventions

  • DeviceVSC-MEDlib

    VSC-MEDlib will be used for post-processing

06

What researchers measure

Primary outcomes

  1. Clinical safety and effectiveness VSC-MEDlib according to IFU

    Clinical safety and effectiveness of the non-invasive and contactless measurement RR by the VSC-MEDlib within the intended use.

    Time frame: 2 hours

  2. Clinical safety and effectiveness VSC-MEDlib according to IFU

    Clinical safety and effectiveness of the non-invasive and contactless measurement of PR by the VSC-MEDlib within the intended use.

    Time frame: 2 hours

Other outcomes

  1. Clinical safety and effectiveness VSC-MEDlib during suboptimal conditions

    Safety and clinical effectiveness during suboptimal conditions, in RMSE, availability, and precision of the non-invasive and contactless measurement of RR by the VSCMEDlib.

    Time frame: 2 hours

  2. Clinical safety and effectiveness VSC-MEDlib during suboptimal conditions

    Safety and clinical effectiveness during suboptimal conditions, in RMSE, availability, and precision of the non-invasive and contactless measurement of PR by the VSCMEDlib.

    Time frame: 2 hours

07

Study locations

1 site
  • Philips
    Eindhoven, North Brabant 5656AE, Netherlands
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06140433
Responsible party
Sponsor
First posted
Nov 20, 2023
Start date
Feb 2, 2024
Primary completion
Mar 15, 2024
Completion
Mar 15, 2024
Last update
Jul 5, 2024

Study contacts

Murk Westerterp
study director · Integrated Technology Solutions

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion